to collect the data necessary to be certain that appropriate use of antibiotics is included in these programs. It should not be ignored that pharmaceutical companies need to ensure that antibiotic drugs are ethically promoted. Lastly, effective hygiene and infection prevention measures can reduce the incidence of infections 3, 4 .
If the world health community is to effectively deal with the threat of AMR, then the above proposals should be systematically and seriously addressed. That means that there must be the concurrent political will to implement them. In the absence of effective measures being taken, it has been estimated that a continued rise in resistance would lead by 2050 to 10 million people dying every year and would cost the world up to $100 trillion 3 . Collaboration and commitment are essential. Increased funding will help but will not be enough. Price ($) 4,000 13 . In addition to questions about clinical utility and payer coverage, panels also raise questions about how to interpret the results given that they return variants of unknown significance and also incidental findings 10, [12] [13] [14] [15] . Furthermore, the services offered by each laboratory may differ, as well as the NGS technologies used to conduct the test. Oversight of NGS technologies, which are used for virtually all of the new tests, contains many gaps 1 . Our analysis did not include an evaluation of the analytic validity of new tests, and only limited studies exist on how newer laboratories compare to Myriad's tests in that regard 12 . The supplementary services offered (follow-up as new results and variant classifications become available, assistance with reimbursement, patient education materials) may also differ between laboratories.
In conclusion, we found that BRCA1/2 test options have increased and prices have decreased. Nearly all payers have positive coverage policies for BRCA1/2-only testing, but despite the increasing availability of panels, private insurers do not currently formally cover these panels. In their coverage documents, payers cited limited data regarding clinical validity and clinical utility as justification for not covering panels, and routine use of panels has not yet been recommended in guidelines 5 . The comparative effectiveness and cost effectiveness of panels versus single-gene tests have also not been established. Future research on these issues will help define the appropriate use of panels and likely lead to changes in payer coverage policies regarding panels. These issues will accelerate in importance as test panels for other genes and conditions enter clinical care. Fig. 1 ). Panels are more expensive than new BRCA1/2-only tests on average (mean price $3,357), but 70% are less expensive than Integrated BRACAnalysis (Fig. 1) . We were unable to access contract pricing or rebating between individual diagnostic providers and payers and therefore cannot comment on the actual cost of each test to payers. However, list prices are indicative of the overall trends in the marketplace.
To evaluate payer coverage of panels, we reviewed publicly available coverage policies from the largest private payers and coded coverage determinations and criteria used (as of May 2015; Supplementary Tables 2 and 3). Although payers with policies about BRCA1/2 testing universally cover two-gene testing in high-risk populations, none of the 17 payers reviewed explicitly covered panels that include BRCA1/2 ( Table 1) , and the majority considered all panels investigational or experimental. Three payers noted that panels may be considered medically necessary only if testing of all included genes are considered medically necessary, effectively excluding all currently available panels. Among payers who offer rationales for their policies on panels, most cite the lack of clinical utility and/or clinical validity (data not shown).
Concerns about reimbursement issues may lead some physicians to avoid tests for which such issues are most common 3 . Because of the lack of coverage for panels, some laboratories may run full panels and bill payers only for the covered BRCA1 and BRCA2 genes; Washington University in St. Louis has had success obtaining reimbursement for their tumor panel using a similar approach 8 . However, one payer in our sample (Humana (Louisville, KY, USA); Supplementary Tables 2 and 3) specifically ruled out that option for BRCA1/2 testing. Additionally, if laboratories bill with the same method for BRCA1/2 testing and for panels, panels may not be covered for patients who have already had BRCA1/2 testing.
Understanding coverage policies is important, even though some panels are currently reimbursed despite the lack of positive coverage policies. We have found that payers are increasingly concerned about their inability to enforce their coverage policies and are thus implementing internal claims reviews and analytics to identify panels and deny related claims 9 . In the future, as the American Medical Association (Chicago) develops specific current procedural terminology codes for genetic panels, payers will be better able to enforce their coverage policies.
Thus, the increase in availability of panels allows physicians and patients to get more information for comparable prices, but it is not yet clear how and when panels should be used. Specific panels recently have been shown to identify more clinically actionable mutations than testing for BRCA1/2 tests alone, providing support for the clinical relevance of panel testing [10] [11] [12] . Even so, the clinical validity and clinical utility of many included genes require further research, and the optimal number and identity of genes to test have not 3 . The financial community has also shown great appetite driven by the promise of high drug prices and recurring payments. However, 'payers, ' either public or private, are concerned with both the price levels routinely mentioned for gene therapies and the pricing and reimbursement (P&R) approaches being proposed. Here we report payer attitudes to P&R for gene therapy. We detail why the payers' view differs from that of industry executives, financial analysts and academic experts. And finally, we provide alternative approaches developed through discussions with payers in the United States and large European countries. Many stakeholders claim that gene therapies require new P&R approaches to achieve a fair recognition of value for developers while providing broad access to patients and an acceptable budget impact on health systems 1 . The current conventional wisdom builds upon two premises. First, gene therapies provide long-term or definitive benefits. Therefore, pricing them as multiples of the yearly cost of expensive drugs such as protein replacement therapies is justified. This leads to prices in excess of $1 million or $1.5 million per treatment. And second, a new reimbursement system is required to absorb such high prices. The most likely approach is a capped annuity with risk sharing, allowing health systems to spread the cost over several years and to limit risk if efficacy is not maintained 1 .
Unfortunately, these premises are strongly questioned by the people who ultimately carry the financial burden of gene therapies: payers. Those who reimburse treatments are skeptical for two main reasons. First, the concept of a capped annuity is theoretically attractive but impossible to implement in most current healthcare systems; and second, pricing a gene therapy as a multiple of the yearly cost of expensive protein replacement therapies is considered highly artificial and unjustified.
Whereas payers understand that P&R systems may need adjustments to accommodate the specificities of gene therapies, they resist a paradigm shift in payment approach. For example, the pharmacy director of a large German sick fund comments, "Gene therapies are like any other therapy. They will be reimbursed based on the value of their patient benefits using existing mechanisms. We will not change our health system to cover for gene therapies but will find ways to make those fit into our pricing and reimbursement processes. "
We contacted 29 payers in the United States and Western Europe to survey their preferred payment method for gene therapies (Box 1). We asked payers to identify their top two choices for payment, either in a theoretical environment without health system constraints or in a real-life setting within the constraints of the health system they are working in (Fig. 1a) .
Similar to other stakeholders, in the absence of health system constraints, payers prefer annuities. Annuities reduce initial financial strain, lead to predictable yearly budget impact and reflect the ongoing value of gene therapy. Capping the accrued annuities also limits overall expense. However, in the real world, approaches based on a lump sum payment represent the large majority (70%) of mentions. This shift in responses is driven primarily by the perceived lack of practicality of annuity-based payments in current health systems.
In many large pharmaceutical markets, people frequently change health plans. Transferring annuity contracts from one plan to another without an associated provision of services is currently not considered possible. Members with previous financial obligations for gene therapy would produce difficult and cumbersome claims processes. Plans could refuse patients or companies with self-funded health insurance could resist hiring new employees with ongoing annuity payments, leading to potential discrimination and associated legal clutter. Lapses in coverage might occur, leaving patients at risk of unbearable out-of-pocket payments.
To overcome these hurdles the creation of federal or regional risk pools has been proposed in various countries. However, implementation will be challenging, as illustrated by the United Kingdom where the Cancer Drugs Fund is under question, and where a Rare Disease Fund is still to be implemented. Within public health systems, long-term funding is not guaranteed and depends on political decisions. In countries with private (at least partially) and competitive health insurance markets, the definition of contributions and of coverage policies will likely create recurrent conflicts. Therefore, a lump sum payment for gene therapy remains the preferred approach in most large Western markets (Supplementary Fig. 1 ).
The payers' perspective on gene therapies
